Answers are grounded in this paper and cite their sources.
Case report shows budesonide treatment improves allograft function in kidney transplant patients, suggesting new therapy options.
Recurrent IgA nephropathy after kidney transplantation remains a major cause of graft dysfunction. This case highlights successful management with targeted‐release budesonide combined with sparsentan, underscoring the importance of early recognition and the promise of emerging therapies to preserve long‐term allograft function.
No takes yet. Share an insight, caveat, or question.
Matarneh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: